Doug Baker
Analyst · Oppenheimer. Please proceed with your question.
Yes. Well, again, it depends on what it is, but back to the things that we're quite confident in around antimicrobial program development, digital, both when you roll it out, et cetera, that takes OpEx costs, not just capital. We've retained all that money in the plan, and it's significant. The reason for that is we know it's absolutely critical to the future. It was before COVID. And I would argue, we think it's even more important now with COVID, so all that stuff remains. And what we're working to do, look, you could go and try to say, my goal is to make 2020 as good as possible. And that's going to be our overarching view. For our business, in our situation, we believe as a team, and we're all like locked in arm on this, that is not the right answer. The right answer is to manage 2020 responsibly and intelligently, but really with a mind on 2021, 2022, et cetera. And that doesn't mean we're going to be foolish or anything else. But I would argue, if you really went after 2020, given this is artificially induced, there is going to be recovery. Nobody's clear exactly how it's going to show up, that taking this and using time to your advantage, and we have the ability to do that given the resiliency of our model and frankly, our balance sheet and cash position. And as a consequence, we're going to allow time to help answer some of these things. So we know how to invest intelligently. We know how to reshape businesses that need to get reshaped intelligently. We're just going to make, I think, moves once instead of multiple times, and organizations don't like multiple upsets. And so that's the tack we're taking. Q2, I could care less about, to be honest. It is -- we'll make money, but I don't care. Spending time on making it look less bad seems like a waste of time. It's a 13-week period. What we want our team focused on is really all the stuff we've been talking about, the investments Christophe has been talking about around digital, connectivity and all that, the new antimicrobial capacity and ideas that we have, how to leverage Bioquell, how do we develop comprehensive programs for reopening and ongoing behavior for clients who need new stuff, et cetera. That's really where we think the money is long-term for -- and how you create value for customers and communities, and that's how you create value for shareholders. And that's the stuff we're all over.